ICU
OF
The Starling Fluid Management Monitoring System is a 100% non-invasive fluid management monitoring system that provides clinicians with the confidence to respond to ever-changing patient status and dose IV fluids according to patient response. The Starling system offers an accurate, reliable and non-invasive method to measure flow at the patient’s core and deliver meaningful insights to guide clinical decision-making.
Rx only. For safe & proper use of the product mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.
The next generation of CRRT
The PrisMax control unit is intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.
Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where removal of plasma components is indicated.
RX Only. For safe and proper use of the devices mentioned herein, please refer to the Operator’s Manual or Instructions for Use.
A flexible, filter-based solution that meets the demands of multiple therapies with a versatile platform that can be customized to specific patient needs.
The Prismaflex Control Unit is intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.
Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.
RX Only. For safe and proper use of the devices mentioned herein, please refer to the Operator’s Manual or Instructions for Use.
The extracorporeal drug overdose and poisoning therapy that operates in combination with the Prismaflex system.
MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.
MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.
RX Only. For safe and proper use of the devices mentioned herein, please refer to the Operator’s Manual or Instructions for Use.
The only FDA approved CRRT replacement solution that contains phosphate in a 5L bag
PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information
Indications
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances
Important Risk Information
PHOXILLUM and PRISMASOL replacement solutions are contraindicated in patients with known hypersensitivities to these products.
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure.
PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.
PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly.
The following adverse reactions have been identified during post-approval use with these or other similar products and therefore may occur with use of PHOXILLUM or PRISMASOL: Metabolic acidosis, hypotension, acid-based disorders, electrolyte imbalances including calcium ionized increased, hyperphosphatemia, hypophosphatemia, fluid imbalance.
Baxter’s CRRT filter sets portfolio includes the AN69 membrane with a unique mechanism of action that adsorbs the higher molecular weight toxins that can be present in patients with AKI.
Simplify electrolyte management with our comprehensive portfolio of CRRT solutions
Baxter Healthcare Corporation has received several Emergency Use Authorizations for products to treat certain patients with confirmed COVID-19 infection.
Please see Emergency Use Authorizations (EUAs) and Intended Use statements for each product. FDA has not cleared or approved the EUA products for the treatment of COVID-19 patients. Rather, the EUAs authorize use of the products for no longer than the duration of the COVID-19 public health emergency.
TrueVue Analytics is a powerful software that lets you easily look at benchmarks and trends in your CRRT program
US Medical Information
Baxter Medical Information works to inform and educate healthcare professionals and patients about our products by providing clinical and scientific information to help support clinical decisions.
Login or Register here for US Medical Information Online, or go to https://Medinfo.baxter.com
US Medical Information Online is a self-service portal intended for Healthcare Professionals or employees of a healthcare institutions to search and download frequently requested product information.
For your convenience US Medical Information representatives are also available by email and phone.
Email: [email protected]
Hospital Products Phone: 1-800-933-0303
Renal Clinical Help Line (RCHL) Peritoneal Dialysis & Hemodialysis:
1-888-736-2543, Option #2
Continuous Renal Replacement Therapy: 1-888-404-ICON (4266)
